8-KRegulation FDExhibits & Filings

QUEST DIAGNOSTICS INC 8-K Report, Regulation FD Disclosure (Mar 11, 2014)

Filed March 11, 2014For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) announced the completion of its acquisition of Solstas Lab Partners Group on March 10, 2014. This strategic acquisition is expected to contribute positively to the company's financial performance. In connection with this transaction, Quest Diagnostics has revised its full-year 2014 financial guidance upwards, indicating increased confidence in future revenue and earnings growth. Despite the positive outlook driven by the acquisition, the company also highlighted that unseasonably harsh winter weather in February has negatively impacted its performance, particularly affecting first-quarter earnings per share by an estimated $0.10. The revised guidance balances the contributions of the new acquisition against the temporary weather-related headwinds, suggesting resilience and a positive underlying business trend.

Key Highlights

  • 1Quest Diagnostics has successfully completed the acquisition of Solstas Lab Partners Group and its subsidiaries.
  • 2Full-year 2014 revenue guidance has been raised to a projected increase of 2% to 4%, up from a previous forecast of flat to a 2% decrease.
  • 3Full-year 2014 adjusted earnings per diluted share guidance has been narrowed and slightly increased to a range of $3.95 to $4.15, from $3.90 to $4.10.
  • 4The updated guidance incorporates the positive impact of the Solstas acquisition.
  • 5The company disclosed that severe winter weather in February negatively impacted performance.
  • 6The estimated impact of the harsh winter weather on first-quarter adjusted earnings per diluted share is approximately $0.10.

Frequently Asked Questions

The primary reason for the upward revision in guidance is the completion of the acquisition of Solstas Lab Partners Group, which is expected to contribute positively to the company's revenue and earnings.

The severe winter weather in February negatively impacted the company's performance, with an estimated impact of approximately $0.10 on first-quarter adjusted earnings per diluted share. This impact has been factored into the updated guidance.

Both full-year 2014 revenue guidance and adjusted earnings per diluted share guidance were revised. Revenue is now expected to increase 2% to 4% (previously flat to down 2%), and adjusted EPS is projected to be between $3.95 and $4.15 (previously $3.90 to $4.10).

The acquisition of Solstas Lab Partners Group is a significant strategic move that contributes to the company's updated financial guidance, suggesting it is expected to enhance Quest Diagnostics' market position and financial performance.